SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

AbbVie Submits FDA Biologics License Application for Etentamig

AbbVie submitted a biologics license application to the U.S. FDA for etentamig for adults with relapsed or refractory multiple myeloma. The company describes etentamig as a second-generation BCMA-directed bispecific antibody T-cell engager.

ABBV

Related stories